The Europe NGS Market size is estimated to be USD 1.34 billion by the end of 2021 and is expected to reach USD 2.71 billion by 2026, showing a CAGR of 15.17% during the forecast period.
Next-generation sequencing has been commonly used in the medical field to determine the patient's genetic composition. For the necessary physical and genetic improvements, the use of NGS has also been used to modify plants and animals. NGS also enables biomarker discovery and genetic disease identification. Therefore, the NGS is used to produce precision medicine for the patient's genetic data to provide the person with personalized care.
Increased usage of personalized medicine, development in NGS bioinformatics and pre sequencing solutions and cloud computing, growth in population, increasing prevalence of infectious diseases, and chronic diseases such as cancer are few factors driving the market growth. Besides, anticipated decrease in the prices of genome sequencing due to the development of rapid, high capacity whole genome sequencers by key players is expected to show an optimistic effect on market penetration rates over the few years.
The extensive use of genomics for medical purposes has a significant effect in the years to come on the development of Europe's next-generation sequencing industry. Genomics consists of different technologies, like next-generation sequencing (NGS), genome editing, gene synthesis, and more.
European Next Generation Sequencing services industry driving factors are quicker and cost-effective sequencing, increasing NGS choice over all other platforms, and increasing hereditary disease prevalence. However, the use of genomics in drug development and discovery, the increasing incidence of cancer and other malignant diseases, and collaborations between businesses, Research & Development centers and universities complement production. The storage and management of data generated by sequencing and its interpretation, high reliability on grants & funding from the government and fall in capital expenditure from academic institutions are critical challenges for Europe's next-generation sequencing market.
This research report segmented and sub-segmented into the following categories:
Regionally, Germany is expected to gain the largest market share in 2017 and maintain its position throughout the forecast period. Europe NGS Market is an increasing number of transfusion procedures that are expected to be the main drivers of market growth. The increase in complex procedures requiring large blood samples (chemotherapy, heart surgery, organ transplants, etc.) can also have a positive impact on the market and the low cost of screening is increasing the widespread use and spread of chronic infectious diseases, especially in developing countries. It is mainly used for the detection of HIV, HCV, and HBV and is recommended for routine use in Europe.
According to the World Health Organization, blood donations increased from 3.4% in 2008 to 3.6% in 2010. About 2 million people in Germany donate blood regularly. In France, NAT is voluntarily implemented to increase the safety of non-enveloped viruses such as the hepatitis A virus (HAV) and parvovirus B19 (B19V).
Leading companies in the Europe Next Generation Sequencing (NGS) Market are Illumina Incorporated, Thermo Fischer Scientific, Life Sciences (Roche), Pacific Biosciences, Life Technologies Corp. (Thermo Fischer Scientific), Macrogen Inc., Partek Inc., Genomatix Software GmbH, Perkin Elmer Inc., GATC Biotech AG, Agilent Technologies Inc., Biomatters Ltd., CLC Bio (Qiagen), BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd., Pacific Biosciences, DNASTAR Inc., Knome Inc., Illumina Inc., and Qiagen N.V.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Product
5.1.1 Software
5.1.2 Services
5.2 By Technology
5.2.1 Whole Targeted Re-Sequencing
5.2.2 Genome Sequencing
5.2.3 De Novo Sequencing
5.2.4 Exome Sequencing
5.2.5 RNA-Seq
5.2.6 ChIP-Seq
5.2.7 Methyl-Seq
5.3 By Application
5.3.1 Diagnostics
5.3.2 Drug Discovery
5.3.3 Biomarker Discovery
5.3.4 Personalized Medicine
5.3.5 Agriculture and Animals Research
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Macrogen Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Thermo Fischer Scientific
8.3 Life Sciences (Roche)
8.4 Pacific Biosciences
8.5 Life Technologies Corp.
8.6 Partek Inc.
8.7 Genomatix Software GmbH
8.8 Perkin Elmer Inc.
8.9 GATC Biotech Ag
8.10 Agilent Technologies Inc.
8.11 Biomatters Ltd.
8.12 CLC Bio (Qiagen)
8.13 Pacific Biosciences
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
